Neural Omega
HealthOverviewOur approach to healthMaia CorpusFor patientsMaia ClinicalFor clinicians
ResearchOverviewOur approach to researchMAR PlatformFor researchersMassa SuiteFor pharma
CompanyAboutTeam and missionMimicryThe scienceEthicsHow we workObservatoryResearch and updates
Language
Contact

Decoding the future.

Open to
Academia, patients, industry
Science
Molecular mimicry
Standards
FHIR · OMOP · EHDS

Infrastructure for new studies, discovery through molecular mimicry and our own research lines in advanced therapies. One continuous line of work, from the first evidence to the next generation of treatments.

Medicine has learnt to treat autoimmunity. Neural Omega Research works to understand it: where pathogen and human proteins resemble each other, and what happens when the immune system cannot tell them apart.

Gather it. Then read it.

Neural Omega Research does two things, and they are one line of work. We gather the evidence autoimmune disease never left written down, and we build the bioinformatics able to interrogate it until it yields answers that hold.

The real course of an autoimmune disease is in no record: it happens between visits. The Neural Omega Health apps build that data layer in the daily life of the patient and their doctor, and from there comes the evidence MAR Platform works on, given by those who choose to share it.

Study-specific consent
Nothing enters research without explicit consent for that study, revocable at any time.1
Structured in OMOP and FHIR
Data is modelled in open standards and under the GDPR, so a study can be replicated at another site and in another country, within the European Health Data Space.2
Separate by design
Partnerships with the pharmaceutical industry run under their own data model, apart from the health apps.

Far on the tree. Close in the molecule.

When a pathogen molecule shares enough sequence or structural resemblance with a human one, the response raised against the first can also recognise the second. These are the cases the literature has documented to date, each with its reference.

  • Homo sapiensHuman reference molecules
Viruses

Outside the cellular tree: viruses share no ancestor with cellular life.

Our own line · publication in preparation

Acanthamoeba sp.

Pathogen molecule
Whole proteome
Human molecule
Monocyte-macrophage system
What was shown
Proteome-wide comparison between the Acanthamoeba proteome and the human monocyte-macrophage system. The results will be presented in its publication.

Level of evidenceProteome-scale screening

Associated disease
Autoimmunity, under study
Reference
Neural Omega · sin publicar
Cladogram based on NCBI Taxonomy; branch length does not represent evolutionary distance. Residue ranges are cited as they appear in the original reference.
Read the science behind it

From noise to signal.

A proteome-scale comparison returns thousands of matches. Almost all are noise. Reducing them to the few that deserve an experiment is not one step: it is six distinct analyses, each looking at something different.5

-1-1-1000111PC 1PC 2PC 3

Alignment of the pathogen proteome against the human one, with the thresholds and multiple-comparison corrections that searching at this scale demands. It is the starting point, and the noisiest one.

  • More than 15 toolsA complete discovery environment, built piece by piece.
  • Our own engineWritten from scratch, line by line, in house.

The platforms of this sphere.

MAR Platform and Massa Suite are the two Neural Omega Research platforms, each with its own website. The computing power is on us: no group needs servers of its own to work on this infrastructure.34

Let's shape it,together.

Research groups, patient organisations, public institutions and pharma R&D teams: the conversation starts with the study you want to run.

  1. Neural Omega processes personal health data in accordance with Regulation (EU) 2016/679 (General Data Protection Regulation), within the European Union.
  2. Designed to follow the HL7 FHIR standard, the OMOP Common Data Model and the framework of Regulation (EU) 2025/327 on the European Health Data Space.
  3. Computing capacity is provided within the European Union. The specific terms depend on each study and the size of each dataset.
  4. The capabilities, availability and status of each platform are detailed on its own website.
  5. The viewer's scenes illustrate each type of analysis in schematic form. Mimetic peptide design is an exploratory line in the field of advanced therapy medicinal products, as defined in Regulation (EC) No 1394/2007.